Background Besides improving glucose control, sodium-glucose co-transporter 2 inhibition
with dapagliflozin reduces blood pressure, body weight and urinary albumin: creatinine ratio …

Background We compared kidney and cardiorenal protection in patients without type 2
diabetes across urine albumin-creatinine ratio (UACR) levels after initiation on dapagliflozin …

Background: Dapagliflozin reduces the risk of end-stage renal disease in patients with
chronic kidney disease. We examined the relative risk of cardiovascular and renal events in …

Objectives The purpose of this paper was to investigate the effects of dapagliflozin in chronic
kidney disease (CKD) patients, with and without heart failure (HF). Background Patients with …

Abstract Aims/hypothesis In the Dapagliflozin and Prevention of Adverse Outcomes in
Chronic Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive …

Background Recent cardiovascular outcome trials have shown that sodium–glucose co-
transporter 2 (SGLT2) inhibitors slow the progression of chronic kidney disease (CKD) in …

Abstract Background The Dapagliflozin and Prevention of Adverse outcomes in Chronic
Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the …

Results Compared with placebo, reductions in HbA1c with dapagliflozin were 0.6%, 0.5%,
and 0.3%, respectively, for each consecutive lower eGFR subgroup (P value interaction< …

Background Patients with chronic kidney disease have a high risk of adverse kidney and
cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease …

This pre-specified analysis of DAPA-CKD assessed the impact of sodium-glucose
cotransporter 2 inhibition on abrupt declines in kidney function in high-risk patients based on …